Asia Pacific Hemophilia Market Size, Share & Industry Trends Analysis Report By Distribution Channel, By Type (Hemophilia A, Hemophilia B), By Treatment Type (Prophylaxis, On-demand, and Cure), By Therapy, By Country and Growth Forecast, 2023 - 2030

The Asia Pacific Hemophilia Market would witness market growth of 7.4% CAGR during the forecast period (2023-2030).

More than 7,000 Australians have been identified with a bleeding problem, according to the Haemophilia Foundation Australia. Leading market participants are receiving lucrative growth prospects as a result of the illness's increased diagnosis rate as well as the expanding popularity of preventative treatments to treat hemophilia. Additionally, numerous campaigns are being organized by governing bodies in various nations to raise awareness of the advantages of early diagnosis and the need to follow the right processes to enable the early screening of newborns, which is encouraging market growth.

By 2024 and 2030, respectively, India Brand Equity Foundation (IBEF) projects that the Indian pharmaceutical market will be worth $65 billion and $130 billion. India currently has a $50 billion pharmaceutical sector. India exports pharmaceuticals to more than 200 nations, making it a significant global exporter of these products. A mean industrial production index of 221.6 was recorded for the fiscal year 2021–2022 in the pharmaceutical, chemical, and botanical product industries. In 2021–2022, $24.6 billion was exported in pharmaceutical and medical products. In addition, the most recent data from the National Health Accounts (NHA) 2022 report from Niti Aayog revealed that India's government health expenditure (GHE) amounted to 1.35% of the country's overall GDP in 2019–20.

Asia Pacific experienced a substantial increase in the proportion of overweight and obese persons over the past 20 years in addition to its rapid expansion. According to the Asian Development Bank, over 40.9% of the adult population in this region is overweight, according to recent statistics. It is commonly recognized that being overweight and obese increases the chance of developing non-communicable diseases. Therefore, the quick rise in excess weight points to significant increases in the costs to the economy and healthcare systems. As a result, the market will expand quickly over the forecast period.

The China market dominated the Asia Pacific Hemophilia Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $1,130.2 million by 2030. The Japan market is registering a CAGR of 6.7% during (2023 - 2030). Additionally, The India market would showcase a CAGR of 8% during (2023 - 2030).

Based on Distribution Channel, the market is segmented into Specialty Pharmacies, and Hospital Pharmacies. Based on Type, the market is segmented into Hemophilia A, Hemophilia B, and Others. Based on Treatment Type, the market is segmented into Prophylaxis, On-demand, and Cure. Based on Therapy, the market is segmented into Factor Replacement Therapy (Recombinant Factor Concentrates, and Plasma-derived Factor Concentrates), Desmopressin & Fibrin Sealants, and Gene Therapy & Monoclonal Antibodies. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

Free Valuable Insights: The Worldwide Hemophilia Market is Projected to reach USD 18.3 Billion by 2030, at a CAGR of 6.2%

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Takeda Pharmaceutical Company Limited, CSL Limited (CSL Behring), Pfizer, Inc., Bayer AG, F. Hoffmann-La Roche Ltd., Novo Nordisk A/S, Octapharma AG, BioMarin Pharmaceutical Inc., Swedish Orphan Biovitrum AB (Investor AB) and Sanofi S.A.

Scope of the Study

Market Segments Covered in the Report:

By Distribution Channel

• Specialty Pharmacies
• Hospital Pharmacies

By Type

• Hemophilia A
• Hemophilia B
• Others

By Treatment Type

• Prophylaxis
• On-demand
• Cure

By Therapy

• Factor Replacement Therapy
  • Recombinant Factor Concentrates
  • Plasma-derived Factor Concentrates
• Desmopressin & Fibrin Sealants
• Gene Therapy & Monoclonal Antibodies

By Country

• China
• Japan
• India
• South Korea
• Singapore
• Malaysia
• Rest of Asia Pacific

Key Market Players

List of Companies Profiled in the Report:

• Takeda Pharmaceutical Company Limited
• CSL Limited (CSL Behring)
• Pfizer, Inc.
• Bayer AG
• F.Hoffmann-La Roche Ltd.
• Novo Nordisk A/S
• Octapharma AG
• BioMarin Pharmaceutical Inc.
• Swedish Orphan Biovitrum AB (Investor AB)
• Sanofi S.A.

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Hemophilia Market, by Distribution Channel
1.4.2 Asia Pacific Hemophilia Market, by Type
1.4.3 Asia Pacific Hemophilia Market, by Treatment Type
1.4.4 Asia Pacific Hemophilia Market, by Therapy
1.4.5 Asia Pacific Hemophilia Market, by Country
1.5 Methodology for the research

Chapter 2. Market At a Glance
2.1 Key Highlights

Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints

Chapter 4. Competition Analysis - Global
4.1 KBV Cardinal Matrix
4.2 Recent Industry Wide Strategic Developments
4.2.1 Partnerships, Collaborations and Agreements
4.2.2 Product Launches and Product Expansions
4.2.3 Acquisition and Mergers
4.2.4 Trials and Approvals
4.3 Top Winning Strategies
4.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
4.3.2 Key Strategic Move: (Product Launches and Product Expansions : 2017, Jun – 2021, Jun) Leading Players
4.4 Porter Five Forces Analysis

Chapter 5. Asia Pacific Hemophilia Market by Distribution Channel
5.1 Asia Pacific Specialty Pharmacies Market by Country
5.2 Asia Pacific Hospital Pharmacies Market by Country

Chapter 6. Asia Pacific Hemophilia Market by Type
6.1 Asia Pacific Hemophilia A Market by Country
6.2 Asia Pacific Hemophilia B Market by Country
6.3 Asia Pacific Others Market by Country

Chapter 7. Asia Pacific Hemophilia Market by Treatment Type
7.1 Asia Pacific Prophylaxis Market by Country
7.2 Asia Pacific On-demand Market by Country
7.3 Asia Pacific Cure Market by Country

Chapter 8. Asia Pacific Hemophilia Market by Therapy
8.1 Asia Pacific Factor Replacement Therapy Market by Country
8.2 Asia Pacific Hemophilia Market by Factor Replacement Therapy Type
8.2.1 Asia Pacific Recombinant Factor Concentrates Market by Country
8.2.2 Asia Pacific Plasma-derived Factor Concentrates Market by Country
8.3 Asia Pacific Desmopressin & Fibrin Sealants Market by Country
8.4 Asia Pacific Gene Therapy & Monoclonal Antibodies Market by Country

Chapter 9. Asia Pacific Hemophilia Market by Country
9.1 China Hemophilia Market
9.1.1 China Hemophilia Market by Distribution Channel
9.1.2 China Hemophilia Market by Type
9.1.3 China Hemophilia Market by Treatment Type
9.1.4 China Hemophilia Market by Therapy
9.1.4.1 China Hemophilia Market by Factor Replacement Therapy Type
9.2 Japan Hemophilia Market
9.2.1 Japan Hemophilia Market by Distribution Channel
9.2.2 Japan Hemophilia Market by Type
9.2.3 Japan Hemophilia Market by Treatment Type
9.2.4 Japan Hemophilia Market by Therapy
9.2.4.1 Japan Hemophilia Market by Factor Replacement Therapy Type
9.3 India Hemophilia Market
9.3.1 India Hemophilia Market by Distribution Channel
9.3.2 India Hemophilia Market by Type
9.3.3 India Hemophilia Market by Treatment Type
9.3.4 India Hemophilia Market by Therapy
9.3.4.1 India Hemophilia Market by Factor Replacement Therapy Type
9.4 South Korea Hemophilia Market
9.4.1 South Korea Hemophilia Market by Distribution Channel
9.4.2 South Korea Hemophilia Market by Type
9.4.3 South Korea Hemophilia Market by Treatment Type
9.4.4 South Korea Hemophilia Market by Therapy
9.4.4.1 South Korea Hemophilia Market by Factor Replacement Therapy Type
9.5 Singapore Hemophilia Market
9.5.1 Singapore Hemophilia Market by Distribution Channel
9.5.2 Singapore Hemophilia Market by Type
9.5.3 Singapore Hemophilia Market by Treatment Type
9.5.4 Singapore Hemophilia Market by Therapy
9.5.4.1 Singapore Hemophilia Market by Factor Replacement Therapy Type
9.6 Malaysia Hemophilia Market
9.6.1 Malaysia Hemophilia Market by Distribution Channel
9.6.2 Malaysia Hemophilia Market by Type
9.6.3 Malaysia Hemophilia Market by Treatment Type
9.6.4 Malaysia Hemophilia Market by Therapy
9.6.4.1 Malaysia Hemophilia Market by Factor Replacement Therapy Type
9.7 Rest of Asia Pacific Hemophilia Market
9.7.1 Rest of Asia Pacific Hemophilia Market by Distribution Channel
9.7.2 Rest of Asia Pacific Hemophilia Market by Type
9.7.3 Rest of Asia Pacific Hemophilia Market by Treatment Type
9.7.4 Rest of Asia Pacific Hemophilia Market by Therapy
9.7.4.1 Rest of Asia Pacific Hemophilia Market by Factor Replacement Therapy Type

Chapter 10. Company Profiles
10.1 Swedish Orphan Biovitrum AB (Investor AB)
10.1.1 Company Overview
10.1.2 Financial Analysis
10.1.3 Segmental and Regional Analysis
10.1.4 Research & Development Expenses
10.1.5 SWOT Analysis
10.2 Takeda Pharmaceutical Company Limited
10.2.1 Company Overview
10.2.2 Financial Analysis
10.2.3 Regional Analysis
10.2.4 Research & Development Expense
10.2.5 Recent strategies and developments:
10.2.5.1 Trials and Approvals:
10.2.5.2 Product Launches and Product Expansions:
10.3 Pfizer, Inc.
10.3.1 Company Overview
10.3.2 Financial Analysis
10.3.3 Regional & Segmental Analysis
10.3.4 Research & Development Expense
10.3.4.1 Partnerships, Collaborations, and Agreements:
10.3.4.2 Acquisition and Mergers:
10.4 CSL Limited (CSL Behring)
10.4.1 Company Overview
10.4.2 Financial Analysis
10.4.3 Segmental and Regional Analysis
10.4.4 Research & Development Expense
10.4.5 Recent strategies and developments:
10.4.5.1 Trials and Approvals:
10.4.5.2 Acquisition and Mergers:
10.4.6 SWOT Analysis
10.5 Octapharma AG
10.5.1 Company Overview
10.5.2 Financial Analysis
10.5.3 Research & Development Expenses
10.5.4 Recent strategies and developments:
10.5.4.1 Trials and Approvals:
10.5.5 SWOT Analysis
10.6 Bayer AG
10.6.1 Company Overview
10.6.2 Financial Analysis
10.6.3 Segmental and Regional Analysis
10.6.4 Research & Development Expense
10.6.5 Recent strategies and developments:
10.6.5.1 Partnerships, Collaborations, and Agreements:
10.6.5.2 Acquisition and Mergers:
10.6.6 SWOT Analysis
10.7 F. Hoffmann-La Roche Ltd.
10.7.1 Company Overview
10.7.2 Financial Analysis
10.7.3 Segmental and Regional Analysis
10.7.4 Research & Development Expense
10.7.5 SWOT Analysis
10.8 Novo Nordisk A/S
10.8.1 Company Overview
10.8.2 Financial Analysis
10.8.3 Segmental & Regional Analysis
10.8.4 Research & Development Expenses
10.8.5 Recent strategies and developments:
10.8.5.1 Partnerships, Collaborations, and Agreements:
10.8.5.2 Product Launches and Product Expansions:
10.8.5.3 Acquisition and Mergers:
10.8.6 SWOT Analysis
10.9 BioMarin Pharmaceutical Inc.
10.9.1 Company Overview
10.9.2 Financial Analysis
10.9.3 Regional Analysis
10.9.4 Research & Development Expenses
10.9.5 Recent strategies and developments:
10.9.5.1 Trials and Approvals:
10.9.6 SWOT Analysis
10.10. Sanofi S.A.
10.10.1 Company Overview
10.10.2 Financial Analysis
10.10.3 Segmental and Regional Analysis
10.10.4 Research & Development Expense
10.10.5 Recent strategies and developments:
10.10.5.1 Trials and Approvals:

TABLE 1 Asia Pacific Hemophilia Market, 2019 - 2022, USD Million
TABLE 2 Asia Pacific Hemophilia Market, 2023 - 2030, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Hemophilia Market
TABLE 4 Product Launches And Product Expansions– Hemophilia Market
TABLE 5 Acquisition and Mergers– Hemophilia Market
TABLE 6 Trials and Approvals– Hemophilia Market
TABLE 7 Asia Pacific Hemophilia Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 8 Asia Pacific Hemophilia Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 9 Asia Pacific Specialty Pharmacies Market by Country, 2019 - 2022, USD Million
TABLE 10 Asia Pacific Specialty Pharmacies Market by Country, 2023 - 2030, USD Million
TABLE 11 Asia Pacific Hospital Pharmacies Market by Country, 2019 - 2022, USD Million
TABLE 12 Asia Pacific Hospital Pharmacies Market by Country, 2023 - 2030, USD Million
TABLE 13 Asia Pacific Hemophilia Market by Type, 2019 - 2022, USD Million
TABLE 14 Asia Pacific Hemophilia Market by Type, 2023 - 2030, USD Million
TABLE 15 Asia Pacific Hemophilia A Market by Country, 2019 - 2022, USD Million
TABLE 16 Asia Pacific Hemophilia A Market by Country, 2023 - 2030, USD Million
TABLE 17 Asia Pacific Hemophilia B Market by Country, 2019 - 2022, USD Million
TABLE 18 Asia Pacific Hemophilia B Market by Country, 2023 - 2030, USD Million
TABLE 19 Asia Pacific Others Market by Country, 2019 - 2022, USD Million
TABLE 20 Asia Pacific Others Market by Country, 2023 - 2030, USD Million
TABLE 21 Asia Pacific Hemophilia Market by Treatment Type, 2019 - 2022, USD Million
TABLE 22 Asia Pacific Hemophilia Market by Treatment Type, 2023 - 2030, USD Million
TABLE 23 Asia Pacific Prophylaxis Market by Country, 2019 - 2022, USD Million
TABLE 24 Asia Pacific Prophylaxis Market by Country, 2023 - 2030, USD Million
TABLE 25 Asia Pacific On-demand Market by Country, 2019 - 2022, USD Million
TABLE 26 Asia Pacific On-demand Market by Country, 2023 - 2030, USD Million
TABLE 27 Asia Pacific Cure Market by Country, 2019 - 2022, USD Million
TABLE 28 Asia Pacific Cure Market by Country, 2023 - 2030, USD Million
TABLE 29 Asia Pacific Hemophilia Market by Therapy, 2019 - 2022, USD Million
TABLE 30 Asia Pacific Hemophilia Market by Therapy, 2023 - 2030, USD Million
TABLE 31 Asia Pacific Factor Replacement Therapy Market by Country, 2019 - 2022, USD Million
TABLE 32 Asia Pacific Factor Replacement Therapy Market by Country, 2023 - 2030, USD Million
TABLE 33 Asia Pacific Hemophilia Market by Factor Replacement Therapy Type, 2019 - 2022, USD Million
TABLE 34 Asia Pacific Hemophilia Market by Factor Replacement Therapy Type, 2023 - 2030, USD Million
TABLE 35 Asia Pacific Recombinant Factor Concentrates Market by Country, 2019 - 2022, USD Million
TABLE 36 Asia Pacific Recombinant Factor Concentrates Market by Country, 2023 - 2030, USD Million
TABLE 37 Asia Pacific Plasma-derived Factor Concentrates Market by Country, 2019 - 2022, USD Million
TABLE 38 Asia Pacific Plasma-derived Factor Concentrates Market by Country, 2023 - 2030, USD Million
TABLE 39 Asia Pacific Desmopressin & Fibrin Sealants Market by Country, 2019 - 2022, USD Million
TABLE 40 Asia Pacific Desmopressin & Fibrin Sealants Market by Country, 2023 - 2030, USD Million
TABLE 41 Asia Pacific Gene Therapy & Monoclonal Antibodies Market by Country, 2019 - 2022, USD Million
TABLE 42 Asia Pacific Gene Therapy & Monoclonal Antibodies Market by Country, 2023 - 2030, USD Million
TABLE 43 Asia Pacific Hemophilia Market by Country, 2019 - 2022, USD Million
TABLE 44 Asia Pacific Hemophilia Market by Country, 2023 - 2030, USD Million
TABLE 45 China Hemophilia Market, 2019 - 2022, USD Million
TABLE 46 China Hemophilia Market, 2023 - 2030, USD Million
TABLE 47 China Hemophilia Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 48 China Hemophilia Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 49 China Hemophilia Market by Type, 2019 - 2022, USD Million
TABLE 50 China Hemophilia Market by Type, 2023 - 2030, USD Million
TABLE 51 China Hemophilia Market by Treatment Type, 2019 - 2022, USD Million
TABLE 52 China Hemophilia Market by Treatment Type, 2023 - 2030, USD Million
TABLE 53 China Hemophilia Market by Therapy, 2019 - 2022, USD Million
TABLE 54 China Hemophilia Market by Therapy, 2023 - 2030, USD Million
TABLE 55 China Hemophilia Market by Factor Replacement Therapy Type, 2019 - 2022, USD Million
TABLE 56 China Hemophilia Market by Factor Replacement Therapy Type, 2023 - 2030, USD Million
TABLE 57 Japan Hemophilia Market, 2019 - 2022, USD Million
TABLE 58 Japan Hemophilia Market, 2023 - 2030, USD Million
TABLE 59 Japan Hemophilia Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 60 Japan Hemophilia Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 61 Japan Hemophilia Market by Type, 2019 - 2022, USD Million
TABLE 62 Japan Hemophilia Market by Type, 2023 - 2030, USD Million
TABLE 63 Japan Hemophilia Market by Treatment Type, 2019 - 2022, USD Million
TABLE 64 Japan Hemophilia Market by Treatment Type, 2023 - 2030, USD Million
TABLE 65 Japan Hemophilia Market by Therapy, 2019 - 2022, USD Million
TABLE 66 Japan Hemophilia Market by Therapy, 2023 - 2030, USD Million
TABLE 67 Japan Hemophilia Market by Factor Replacement Therapy Type, 2019 - 2022, USD Million
TABLE 68 Japan Hemophilia Market by Factor Replacement Therapy Type, 2023 - 2030, USD Million
TABLE 69 India Hemophilia Market, 2019 - 2022, USD Million
TABLE 70 India Hemophilia Market, 2023 - 2030, USD Million
TABLE 71 India Hemophilia Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 72 India Hemophilia Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 73 India Hemophilia Market by Type, 2019 - 2022, USD Million
TABLE 74 India Hemophilia Market by Type, 2023 - 2030, USD Million
TABLE 75 India Hemophilia Market by Treatment Type, 2019 - 2022, USD Million
TABLE 76 India Hemophilia Market by Treatment Type, 2023 - 2030, USD Million
TABLE 77 India Hemophilia Market by Therapy, 2019 - 2022, USD Million
TABLE 78 India Hemophilia Market by Therapy, 2023 - 2030, USD Million
TABLE 79 India Hemophilia Market by Factor Replacement Therapy Type, 2019 - 2022, USD Million
TABLE 80 India Hemophilia Market by Factor Replacement Therapy Type, 2023 - 2030, USD Million
TABLE 81 South Korea Hemophilia Market, 2019 - 2022, USD Million
TABLE 82 South Korea Hemophilia Market, 2023 - 2030, USD Million
TABLE 83 South Korea Hemophilia Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 84 South Korea Hemophilia Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 85 South Korea Hemophilia Market by Type, 2019 - 2022, USD Million
TABLE 86 South Korea Hemophilia Market by Type, 2023 - 2030, USD Million
TABLE 87 South Korea Hemophilia Market by Treatment Type, 2019 - 2022, USD Million
TABLE 88 South Korea Hemophilia Market by Treatment Type, 2023 - 2030, USD Million
TABLE 89 South Korea Hemophilia Market by Therapy, 2019 - 2022, USD Million
TABLE 90 South Korea Hemophilia Market by Therapy, 2023 - 2030, USD Million
TABLE 91 South Korea Hemophilia Market by Factor Replacement Therapy Type, 2019 - 2022, USD Million
TABLE 92 South Korea Hemophilia Market by Factor Replacement Therapy Type, 2023 - 2030, USD Million
TABLE 93 Singapore Hemophilia Market, 2019 - 2022, USD Million
TABLE 94 Singapore Hemophilia Market, 2023 - 2030, USD Million
TABLE 95 Singapore Hemophilia Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 96 Singapore Hemophilia Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 97 Singapore Hemophilia Market by Type, 2019 - 2022, USD Million
TABLE 98 Singapore Hemophilia Market by Type, 2023 - 2030, USD Million
TABLE 99 Singapore Hemophilia Market by Treatment Type, 2019 - 2022, USD Million
TABLE 100 Singapore Hemophilia Market by Treatment Type, 2023 - 2030, USD Million
TABLE 101 Singapore Hemophilia Market by Therapy, 2019 - 2022, USD Million
TABLE 102 Singapore Hemophilia Market by Therapy, 2023 - 2030, USD Million
TABLE 103 Singapore Hemophilia Market by Factor Replacement Therapy Type, 2019 - 2022, USD Million
TABLE 104 Singapore Hemophilia Market by Factor Replacement Therapy Type, 2023 - 2030, USD Million
TABLE 105 Malaysia Hemophilia Market, 2019 - 2022, USD Million
TABLE 106 Malaysia Hemophilia Market, 2023 - 2030, USD Million
TABLE 107 Malaysia Hemophilia Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 108 Malaysia Hemophilia Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 109 Malaysia Hemophilia Market by Type, 2019 - 2022, USD Million
TABLE 110 Malaysia Hemophilia Market by Type, 2023 - 2030, USD Million
TABLE 111 Malaysia Hemophilia Market by Treatment Type, 2019 - 2022, USD Million
TABLE 112 Malaysia Hemophilia Market by Treatment Type, 2023 - 2030, USD Million
TABLE 113 Malaysia Hemophilia Market by Therapy, 2019 - 2022, USD Million
TABLE 114 Malaysia Hemophilia Market by Therapy, 2023 - 2030, USD Million
TABLE 115 Malaysia Hemophilia Market by Factor Replacement Therapy Type, 2019 - 2022, USD Million
TABLE 116 Malaysia Hemophilia Market by Factor Replacement Therapy Type, 2023 - 2030, USD Million
TABLE 117 Rest of Asia Pacific Hemophilia Market, 2019 - 2022, USD Million
TABLE 118 Rest of Asia Pacific Hemophilia Market, 2023 - 2030, USD Million
TABLE 119 Rest of Asia Pacific Hemophilia Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 120 Rest of Asia Pacific Hemophilia Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 121 Rest of Asia Pacific Hemophilia Market by Type, 2019 - 2022, USD Million
TABLE 122 Rest of Asia Pacific Hemophilia Market by Type, 2023 - 2030, USD Million
TABLE 123 Rest of Asia Pacific Hemophilia Market by Treatment Type, 2019 - 2022, USD Million
TABLE 124 Rest of Asia Pacific Hemophilia Market by Treatment Type, 2023 - 2030, USD Million
TABLE 125 Rest of Asia Pacific Hemophilia Market by Therapy, 2019 - 2022, USD Million
TABLE 126 Rest of Asia Pacific Hemophilia Market by Therapy, 2023 - 2030, USD Million
TABLE 127 Rest of Asia Pacific Hemophilia Market by Factor Replacement Therapy Type, 2019 - 2022, USD Million
TABLE 128 Rest of Asia Pacific Hemophilia Market by Factor Replacement Therapy Type, 2023 - 2030, USD Million
TABLE 129 Key Information – Swedish Orphan Biovitrum AB
TABLE 130 Key Information – Takeda Pharmaceutical Company Limited
TABLE 131 Key Information – Pfizer, Inc.
TABLE 132 Key Information – CSL Limited
TABLE 133 Key Information – Octapharma AG
TABLE 134 Key Information – Bayer AG
TABLE 135 Key Information – F. Hoffmann-La Roche Ltd.
TABLE 136 Key Information – Novo Nordisk A/S
TABLE 137 Key Information – BioMarin Pharmaceutical Inc.
TABLE 138 Key Information – Sanofi S.A.

List of Figures
FIG 1 Methodology for the research
FIG 2 Asia Pacific Hemophilia Market, 2019 - 2030, USD Million
FIG 3 Key Factors Impacting the Hemophilia Market
FIG 4 KBV Cardinal Matrix
FIG 5 Key Leading Strategies: Percentage Distribution (2019-2023)
FIG 6 Key Strategic Move: (Product Launches and Product Expansions : 2017, Jun – 2021, Jun) Leading Players
FIG 7 Porter’s Five Forces Analysis –Hemophilia Market
FIG 8 Asia Pacific Hemophilia Market share by Distribution Channel, 2022
FIG 9 Asia Pacific Hemophilia Market share by Distribution Channel, 2030
FIG 10 Asia Pacific Hemophilia Market by Distribution Channel, 2019 - 2030, USD Million
FIG 11 Asia Pacific Hemophilia Market share by Type, 2022
FIG 12 Asia Pacific Hemophilia Market share by Type, 2030
FIG 13 Asia Pacific Hemophilia Market by Type, 2019 - 2030, USD Million
FIG 14 Asia Pacific Hemophilia Market share by Treatment Type, 2022
FIG 15 Asia Pacific Hemophilia Market share by Treatment Type, 2030
FIG 16 Asia Pacific Hemophilia Market by Treatment Type, 2019 - 2030, USD Million
FIG 17 Asia Pacific Hemophilia Market share by Therapy, 2022
FIG 18 Asia Pacific Hemophilia Market share by Therapy, 2030
FIG 19 Asia Pacific Hemophilia Market by Therapy, 2019 - 2030, USD Million
FIG 20 Asia Pacific Hemophilia Market share by Country, 2022
FIG 21 Asia Pacific Hemophilia Market share by Country, 2030
FIG 22 Asia Pacific Hemophilia Market by Country, 2019 - 2030, USD Million
FIG 23 SWOT Analysis: Swedish Orphan Biovitrum AB
FIG 24 SWOT Analysis: CSL Limited
FIG 25 SWOT Analysis: Octapharma AG
FIG 26 SWOT Analysis: Bayer AG
FIG 27 SWOT Analysis: F. Hoffmann-La Roche Ltd.
FIG 28 Recent strategies and developments: Novo Nordisk A/S
FIG 29 SWOT Analysis: Novo Nordisk A/S
FIG 30 SWOT Analysis: BioMarin Pharmaceutical Inc.